Abstract
Without drug treatment, invasive fungal infections are associated with
very high mortality. The use of antifungal agents needs to be
personalised with regards to infective agent, dose regimen, drug-drug
interactions, and tolerability or drug safety issues. Therapeutic drug
monitoring (TDM) may help to optimise drug therapy in the individual
case, but the clinical indications for TDM differ between different
antifungal agents. Here, we aim to summarise the current, clinical view
on antifungal TDM in relationship to the clinical pharmacology of each
drug.